Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for misleading statements regarding its business performance and product demand during the specified Class Period from February 16, 2023, to February 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical made false and misleading statements about its visibility into customer demand and the impact of COVID-related product destocking, while in reality, it was experiencing significant destocking in its High-Value Products portfolio [5]. - It is alleged that West's SmartDose device, intended as a high-margin growth product, negatively impacted profit margins due to operational inefficiencies [5]. - The lawsuit also highlights that margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [5]. - As a result of these issues, the positive statements made by the defendants regarding West's business and prospects were materially false or misleading [5]. Group 2: Participation Information - Investors who purchased West common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. for alleged securities fraud affecting investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were adversely affected by alleged securities fraud during the specified period [2]. - The complaint alleges that West Pharmaceutical Services made false statements regarding customer demand and operational performance, particularly concerning its high-margin HVP portfolio and the SmartDose device [3]. - Specific allegations include that West was experiencing significant destocking in its HVP portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device was described as dilutive to profit margins due to operational inefficiencies, contradicting its positioning as a high-margin growth product [3]. - The lawsuit also highlights potential risks of costly restructuring activities, including the exit from continuous glucose monitoring contracts with longstanding customers [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=148453&fro ...

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. on behalf of shareholders who purchased common stock between February 16, 2023, and February 12, 2025, alleging misleading statements and operational inefficiencies that negatively impacted the company's financial performance [1][5]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical made false and misleading statements regarding customer demand and product performance, particularly in its High-Value Products portfolio [5]. - It is alleged that the SmartDose device, intended as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [5]. - The lawsuit also highlights risks of costly restructuring activities, including the exit from continuous glucose monitoring contracts, as a result of margin pressures [5]. Group 2: Participation Information - Shareholders who purchased stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by July 7, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements, ranking in the top 4 since 2013 [4].

Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and operational inefficiencies impacting financial performance [1][3][4]. Company Overview - West Pharmaceutical designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products [2]. Allegations of the Lawsuit - The lawsuit alleges that West Pharmaceutical made false statements regarding customer demand and failed to disclose significant destocking in its High-Value Products portfolio [3]. - It is claimed that the SmartDose device, intended as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [3]. - The lawsuit also points out that margin pressures could lead to costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [3]. Financial Impact - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to the loss of two major continuous glucose monitoring customers transitioning to in-house manufacturing, as well as the SmartDose wearable injector becoming margin dilutive due to lower pricing [4]. - Following this announcement, West Pharmaceutical's stock price fell by more than 38% [4].

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a memb ...

According to the complaint, during the class period, defendants failed to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) t ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147742&fro ...

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147732&from=4 CLA ...